Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status.
|
31177911 |
2020 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The Loss of <i>SMAD4/DPC4</i> Expression Associated with a Strongly Activated Hedgehog Signaling Pathway Predicts Poor Prognosis in Resected Pancreatic Cancer.
|
31417657 |
2019 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
As a central player in TGF-β signal transduction, SMAD4 (also known as DPC4) is frequently mutated or deleted in gastrointestinal and pancreatic cancer.
|
30664791 |
2019 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We explored the role of S100A11 in the proliferation and apoptosis of pancreatic cancer cell line PANC-1 and the potential mechanisms involving the TGF-β<sub>1</sub>/SMAD4/p21 pathway.
|
29922945 |
2019 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer.
|
31611300 |
2019 |
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
More interestingly, we observed that the protein level of SMAD4 is inversely correlated with autophagy in orthotopic tumor tissue samples.<b>Conclusions:</b> Our results demonstrate that defective <i>SMAD4</i> is responsible for radioresistance in pancreatic cancer through induction of ROS and increased level of radiation-induced autophagy.<i></i>.
|
29602802 |
2018 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, <i>smad4/DPC4</i> is also mutated in other conditions and cancers such as juvenile polyposis syndrome with and without hereditary haemorrhagic telangiectasia, colorectal and prostate cancers.Immunohistochemistry for smad4/DPC4 protein is most useful in separating benign/reactive conditions from pancreatic cancer in needle/core biopsies.
|
29720405 |
2018 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients.
|
28983662 |
2018 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
|
28099251 |
2017 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The combination of mutant KRAS with a single inactivating TP53, SMAD4 or CDKN2A mutation in genetically engineered mouse models (GEMMs) showed that these mutations exert different synergistic effects in PC.
|
28475592 |
2017 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The most consistently mutated genes are <i>KRAS, CDKN2A, TP53</i>, and <i>SMAD4/DPC4</i> Study of familial PDAC has led to the recognition that a variety of defects in DNA repair genes can be associated with the emergence of pancreatic cancer.
|
28373361 |
2017 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
SUVmax can predict loss of SMAD4 in resected left-sided pancreatic cancer.
|
27124039 |
2016 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We have tested nanopore sequencing to detect a series of well-characterized SVs, including large deletions, inversions, and translocations that inactivate the CDKN2A/p16 and SMAD4/DPC4 tumor suppressor genes in pancreatic cancer.
|
26787508 |
2016 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Eighteen phenotypic markers representing 11 types of IIC and the protein products of genes TP53, CDKN2A/p16 and SMAD4/DPC4 were assessed by immunohistochemistry of specimens from patients with pancreatic cancer.
|
27256393 |
2016 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize the role of several miRNAs that regulate various oncogenes (KRAS) and tumor suppressor genes (p53, p16, SMAD4, etc.) involved in PC development, their prospective roles as diagnostic and prognostic markers and as a therapeutic targets.
|
25453266 |
2015 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We investigated how maintenance of pancreatic cancer-initiating cells is influenced by Smad4, which is frequently deleted or mutated in pancreatic cancers cells.
|
25769430 |
2015 |
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.
|
26019136 |
2015 |
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
DPC4/SMAD4 mutations are associated with aggressive pancreatic cancer.In this issue of Cell, Whittle et al. demonstrate that Runx3 expression combined with Dpc4/Smad4 status can predict the metastatic propensity of pancreatic tumors, providing valuable guidance for personalized therapy for patients with pancreatic cancer.
|
26046433 |
2015 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Other genetic alterations, including telomere shortening and the inactivation of tumor suppressor genes such as CDKN2A, TP53, and SMAD4, which encode p16, p53, and SMAD4, respectively, also contribute to the progression of pancreatic cancer.
|
24445769 |
2015 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
This study was performed to examine the expression patterns and association of Jab1 and Smad4 in PC cells for gaining a further understanding of PC pathogenesis.
|
26464677 |
2015 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Insights Into SMAD4 Loss in Pancreatic Cancer From Inducible Restoration of TGF-β Signaling.
|
26284758 |
2015 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Transforming growth factor, beta (TGFB) signal is considered to be a tumor suppressive pathway based on the frequent genomic deletion of the SMAD4 gene in pancreatic cancer (PC); however; the role of the activin signal, which also belongs to the TGFB superfamily, remains largely unclear.
|
24886203 |
2014 |
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We found that (i) differentially expressed whole cell and cytoplasm RNA levels are both poor predictors of polysome RNA levels; (ii) for a majority of RNAs, differential RNA levels are regulated independently in the nucleus, cytoplasm, and polysomes; (iii) for most of the remaining polysome RNA, levels are regulated via a "tagging" of the RNAs in the nucleus for rapid entry into the polysomes; (iv) a SMAD4-dependent pathway appears to indeed play a role in regulating mRNA entry into polysomes; and (v) a gene list derived from differentially expressed polysome RNA in BxPC3 cells generated new candidate genes and cell pathways potentially related to pancreatic cancer.
|
22965423 |
2012 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Genetic alterations of KRAS, CDKN2A, TP53, and SMAD4 are the most frequent events in pancreatic cancer.
|
22991414 |
2012 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Genetic mutations, such as activation of the KRAS2 oncogene, inactivation of the tumor-suppressor gene CDKN2A, inactivation of the tumor-suppressor gene TP53 and deleted in pancreatic cancer 4 (DPC4) gene defects are seen in those with pancreatic cancer.
|
23393682 |
2012 |